177 related articles for article (PubMed ID: 37550002)
1. Benralizumab for eosinophilic granulomatosis with polyangiitis.
Cottu A; Groh M; Desaintjean C; Marchand-Adam S; Guillevin L; Puechal X; Beaumesnil S; Lazaro E; Samson M; Taille C; Durel CA; Diot E; Nicolas S; Guilleminault L; Ebbo M; Cathebras P; Dupin C; Yildiz H; Belfeki N; Pugnet G; Chauvin P; Jouneau S; Lifermann F; Martellosio JP; Cottin V; Terrier B;
Ann Rheum Dis; 2023 Dec; 82(12):1580-1586. PubMed ID: 37550002
[TBL] [Abstract][Full Text] [Related]
2. Dupilumab for relapsing or refractory sinonasal and/or asthma manifestations in eosinophilic granulomatosis with polyangiitis: a European retrospective study.
Molina B; Padoan R; Urban ML; Novikov P; Caminati M; Taillé C; Néel A; Bouillet L; Fraticelli P; Schleinitz N; Christides C; Moi L; Godeau B; Knight A; Schroeder JW; Marchand-Adam S; Gil H; Cottin V; Durel CA; Gelain E; Lerais B; Ruivard M; Groh M; Samson M; Moroni L; Thiel J; Kernder A; Cohen Tervaert JW; Costanzo G; Folci M; Rizzello S; Cohen P; Emmi G; Terrier B
Ann Rheum Dis; 2023 Dec; 82(12):1587-1593. PubMed ID: 37734881
[TBL] [Abstract][Full Text] [Related]
3. Benralizumab for eosinophilic granulomatosis with polyangiitis: a retrospective, multicentre, cohort study.
Bettiol A; Urban ML; Padoan R; Groh M; Lopalco G; Egan A; Cottin V; Fraticelli P; Crimi C; Del Giacco S; Losappio L; Moi L; Cinetto F; Caminati M; Novikov P; Berti A; Cameli P; Cathébras P; Coppola A; Durel CA; Folci M; Lo Gullo A; Lombardi C; Monti S; Parronchi P; Rivera CM; Solans R; Vacca A; Espígol-Frigolé G; Guarnieri G; Bianchi FC; Marchi MR; Tcherakian C; Kahn JE; Iannone F; Venerito V; Desaintjean C; Moroncini G; Nolasco S; Costanzo GAML; Schroeder JW; Ribi C; Tesi M; Gelain E; Mattioli I; Bello F; Jayne D; Prisco D; Vaglio A; Emmi G;
Lancet Rheumatol; 2023 Dec; 5(12):e707-e715. PubMed ID: 38251561
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness and safety of anti-IL-5/Rα biologics in eosinophilic granulomatosis with polyangiitis: a two-year multicenter observational study.
Nolasco S; Portacci A; Campisi R; Buonamico E; Pelaia C; Benfante A; Triggiani M; Spadaro G; Caiaffa MF; Scioscia G; Detoraki A; Valenti G; Papia F; Tomasello A; Crimi N; Scichilone N; Pelaia G; Carpagnano GE; Crimi C
Front Immunol; 2023; 14():1204444. PubMed ID: 37457743
[TBL] [Abstract][Full Text] [Related]
5. Response to mepolizumab according to disease manifestations in patients with eosinophilic granulomatosis with polyangiitis.
Ríos-Garcés R; Prieto-González S; Hernández-Rodríguez J; Arismendi E; Alobid I; Penatti AE; Cid MC; Espígol-Frigolé G
Eur J Intern Med; 2022 Jan; 95():61-66. PubMed ID: 34535374
[TBL] [Abstract][Full Text] [Related]
6. Mepolizumab exerts crucial effects on glucocorticoid discontinuation in patients with eosinophilic granulomatosis with polyangiitis: a retrospective study of 27 cases at a single center in Japan.
Yamane T; Hashiramoto A
Arthritis Res Ther; 2023 Jun; 25(1):110. PubMed ID: 37365612
[TBL] [Abstract][Full Text] [Related]
7. Long-term Safety and Efficacy of Benralizumab for Eosinophilic Granulomatosis with Polyangiitis Complicated with Severe Neuropathy.
Koga Y; Yoshimi S; Harada T; Suzuki S; Ohtsuka T; Dobashi K; Hisada T
Intern Med; 2023 May; 62(10):1553-1556. PubMed ID: 36171130
[TBL] [Abstract][Full Text] [Related]
8. New-onset of eosinophilic granulomatosis with polyangiitis without eosinophilia and eosinophilic infiltration under benralizumab treatment: A case report.
Yonezawa H; Ohmura SI; Ohkubo Y; Otsuki Y; Miyamoto T
Mod Rheumatol Case Rep; 2023 Dec; 8(1):145-149. PubMed ID: 37243733
[TBL] [Abstract][Full Text] [Related]
9. Benralizumab versus Mepolizumab for Eosinophilic Granulomatosis with Polyangiitis.
Wechsler ME; Nair P; Terrier B; Walz B; Bourdin A; Jayne DRW; Jackson DJ; Roufosse F; Börjesson Sjö L; Fan Y; Jison M; McCrae C; Necander S; Shavit A; Walton C; Merkel PA;
N Engl J Med; 2024 Mar; 390(10):911-921. PubMed ID: 38393328
[TBL] [Abstract][Full Text] [Related]
10. Torasemide-induced Vascular Purpura in the Course of Eosinophilic Granulomatosis with Polyangiitis.
Frątczak A; Polak K; Miziołek B; Bergler-Czop B
Acta Dermatovenerol Croat; 2022 Sep; 30(2):116-118. PubMed ID: 36254546
[TBL] [Abstract][Full Text] [Related]
11. Benralizumab as a Steroid-Sparing Treatment Option in Eosinophilic Granulomatosis with Polyangiitis.
Guntur VP; Manka LA; Denson JL; Dunn RM; Dollin YT; Gill M; Kolakowski C; Strand MJ; Wechsler ME
J Allergy Clin Immunol Pract; 2021 Mar; 9(3):1186-1193.e1. PubMed ID: 33065367
[TBL] [Abstract][Full Text] [Related]
12. [Anti-IL-5 in severe asthma associated with eosinophilic granulomatosis with polyangiitis. Real-life study].
Akdime F; Habib S; Regard L; Terrier B; Cohen P; Mouthon L; Guillevin L; Burgel PR; Honore I; Puéchal X; Roche N
Rev Mal Respir; 2023; 40(9-10):732-742. PubMed ID: 37923651
[TBL] [Abstract][Full Text] [Related]
13. Long-Term Effectiveness of Benralizumab in Eosinophilic Granulomatosis With Polyangiitis.
Nanzer AM; Maynard-Paquette AC; Alam V; Green L; Thomson L; Lam J; Fernandes M; Roxas C; d'Ancona G; Hearn A; Gates J; Agarwal S; Kent BD; Fernando M; D'Cruz DP; Hopkins C; Ismail TF; Dhariwal J; Jackson DJ
J Allergy Clin Immunol Pract; 2024 Mar; 12(3):724-732. PubMed ID: 38211889
[TBL] [Abstract][Full Text] [Related]
14. [Benralizumab in cases of eosinophilic granulomatosis with polyangiitis].
Carrette A; Mercier V; Lelubre C; Peché R
Rev Mal Respir; 2022 Sep; 39(7):621-625. PubMed ID: 35909008
[TBL] [Abstract][Full Text] [Related]
15. Mepolizumab and benralizumab in patients with severe asthma and a history of eosinophilic granulomatosis with polyangiitis.
Desaintjean C; Ahmad K; Traclet J; Gerfaud-Valentin M; Durel CA; Glerant JC; Hot A; Lestelle F; Mainbourg S; Nasser M; Seve P; Turquier S; Devouassoux G; Cottin V
Front Med (Lausanne); 2024; 11():1341310. PubMed ID: 38585151
[TBL] [Abstract][Full Text] [Related]
16. Rapid effect of benralizumab in exacerbation of severe eosinophilic asthma associated with eosinophilic granulomatosis with polyangiitis.
Martínez-Rivera C; Garcia-Olivé I; Urrutia-Royo B; Basagaña-Torrento M; Rosell A; Abad J
BMC Pulm Med; 2021 Jan; 21(1):35. PubMed ID: 33478439
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness of Low-Dose Mepolizumab in the Treatment of Eosinophilic Granulomatosis with Polyangiitis (EGPA): A Real-Life Experience.
Özdel Öztürk B; Yavuz Z; Aydın Ö; Mungan D; Sin BA; Demirel YS; Bavbek S
Int Arch Allergy Immunol; 2022; 183(12):1281-1290. PubMed ID: 36126640
[TBL] [Abstract][Full Text] [Related]
18. Advances in the pharmacotherapeutic management of eosinophilic granulomatosis with polyangiitis.
Pagnoux C; Berti A
Expert Opin Pharmacother; 2023; 24(11):1269-1281. PubMed ID: 37204027
[TBL] [Abstract][Full Text] [Related]
19. Eosinophilic granulomatosis with polyangiitis developed after dupilumab administration in patients with eosinophilic chronic rhinosinusitis and asthma: a case report.
Suzaki I; Tanaka A; Yanai R; Maruyama Y; Kamimura S; Hirano K; Kobayashi H
BMC Pulm Med; 2023 Apr; 23(1):130. PubMed ID: 37076824
[TBL] [Abstract][Full Text] [Related]
20. [SUCCESSFUL TREATMENT FOR OTITIS MEDIA AND SINUSITIS ASSOCIATED WITH EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS USING ANTI-IL-5 RECEPTOR MONOCLONAL ANTIBODY BENRALIZUMAB].
Sugiyama T; Yoshida S; Kikuchi S; Iino Y
Arerugi; 2022; 71(3):242-247. PubMed ID: 35569946
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
